15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering PTC Therapeutics Inc, 10 rate it Buy or better, 1 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets range widely, $50.00 to $130.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $92.58 sits 22% above the current $75.79. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.48 next quarter toward $2.74 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Moderate Buy
Strong Buy00%
Buy1083%
Hold18%
Sell18%
Strong Sell00%
Based on 12 analysts giving stock ratings to PTC Therapeutics Inc.
As of Jul, 8 of 10 firms rate PTCT a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
PTCT EPS & revenue forecast
EPS · NEXT QUARTER
$0.48
Range $0.29 – $0.74 · 3 analysts · +155% YoY
Next period, 3 analysts expect PTC Therapeutics Inc to earn $0.48 a share (range $0.29 – $0.74), versus $0.19 a year earlier. Full-year consensus is $1.32, growing to $2.74 the year after.
REVENUE · NEXT QUARTER
$298.2M
Range $258.7M – $332.3M · 3 analysts · +41% YoY
Revenue is expected to reach $298.2M (range $258.7M – $332.3M), +41.3% year-over-year. Full-year consensus is $1.2B, rising to $1.3B next year.
Top analysts covering PTC Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PTCT.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #12
Buy
$92.00+21.4% to target
Overall win rate
61%
+ Follow
#2
Joel Beatty
Baird · Rank #111
Buy
$70.00-7.6% to target
Overall win rate
46%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$130.00+71.5% to target
Overall win rate
38%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
No targeton PTCT
Overall win rate
41%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #311
Hold
$85.00+12.2% to target
Overall win rate
25%
+ Follow
PTCT stock forecast FAQ
What is PTCT's average 12-month price target?+
The 12 analysts with a live target average $92.58 for PTC Therapeutics Inc over the next 12 months, ranging from a $130.00 high to a $50.00 low.
Is PTCT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 12 analyst ratings, 10 are Buy or Strong Buy, 1 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for PTCT?+
The Street-high target is $130.00 (Cantor Fitzgerald), and the Street-low is $50.00 (Goldman Sachs). The average of all 12 active targets is $92.58.
How many Wall Street analysts cover PTCT?+
12 analysts have an active rating on PTC Therapeutics Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering PTCT?+
Among analysts who currently cover PTCT, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #12). Their current call is Buy with a $92.00 target.
What is PTC Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.48 per share (range $0.29 – $0.74) across 3 analysts. Full-year EPS is projected at $1.32, rising to $2.74 the following year.
How much revenue is PTC Therapeutics Inc expected to report next quarter?+
Consensus revenue is $298.2M (range $258.7M – $332.3M). Full-year revenue is projected at $1.2B, growing to $1.3B next year.
Have analysts been upgrading or downgrading PTCT lately?+
As of Jul, 8 of 10 firms rate PTCT a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PTCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
